SELECT Trial: Semaglutide Protects Heart Independent

The SELECT trial has been a landmark in cardiology since 2023, showing that semaglutide (Wegovy) reduces major adverse cardiovascular events (MACE) by 20% in people with overweight or obesity and established cardiovascular disease - but without diabetes. Now, two new analyses provide groundbreaking details on how this protection works.

Why does semaglutide protect the heart even without major weight loss?

A prespecified secondary analysis published in The Lancet in October 2025 examined exactly this question. The result: The cardioprotective effect of semaglutide was independent of baseline body weight, waist circumference, and the amount of weight lost. Even participants with minimal weight reduction experienced significant benefits. The authors, led by Prof. John Deanfield, conclude that semaglutide and other GLP-1 receptor agonists should be re-evaluated as disease-modifying treatments - not solely as weight-loss or glycemic-control medications. This has direct implications for prescribing policies: BMI thresholds or weight-loss targets may inappropriately restrict access for patients who would still benefit.

What about kidney outcomes in SELECT?

A parallel analysis published in Nature Medicine (2024, updated 2025) examined kidney endpoints in the SELECT trial. The composite kidney endpoint (death from kidney disease, dialysis, persistent ≥50% eGFR decline, or macroalbuminuria) occurred in 1.8% vs. 2.2% - a 22% risk reduction (HR 0.78; p=0.02). The benefit was most pronounced in patients with pre-existing kidney impairment (eGFR <60 ml/min). This suggests a genuine nephroprotective effect beyond weight loss.

What do these findings mean in practice?

The SELECT secondary analyses suggest that semaglutide acts directly on the vascular wall and on inflammatory pathways - independently of its metabolic effects. For patients with cardiovascular disease and overweight, this means a treatment attempt may be worthwhile even if substantial weight loss is not expected. For more details on mechanisms and evidence, see our semaglutide evidence profile and the tirzepatide comparison.

Medical disclaimer: This article is for informational and educational purposes only and does not constitute medical advice. Consult your healthcare provider before starting any therapy with semaglutide or other GLP-1 medications.